Neos Therapeutics

General Information

We are a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing our proprietary modified-release drug delivery technology platform, which we have already used to develop our three branded product candidates for the treatment of attention deficit hyperactivity disorder, or ADHD. Our product candidates are extended-release, or XR, medications in patient-friendly, orally disintegrating tablets, or ODT, or liquid suspension dosage forms. We have a Prescription Drug User Fee Act, or PDUFA, goal date of November 9, 2015 for NT-0102, our methylphenidate XR-ODT. A PDUFA goal date is a review performance goal for the FDA to meet in acting on a new drug application, or NDA. Under PDUFA, as amended by the Food and Drug Administration Safety and Innovation Act, for fiscal year 2015, the FDA agreed to review and act on 90 percent of standard, non-new molecular entity NDAs, like the one submitted for NT-0102, within 10 months from the FDA’s receipt of the NDA submission. We expect to resubmit a new drug application, or NDA, for NT-0202, our amphetamine XR-ODT, by July 2015 and submit an NDA for NT-0201, our amphetamine XR liquid suspension, in the third quarter of 2015. If approved, we believe our product candidates will address an unmet need by providing more patient- and caregiver-friendly dosing options not previously available to patients in the $10.7 billion market for ADHD-indicated medications.

Employees: 59
Founded: 2009
Contact Information
Address 2940 N. Hwy 360, Grand Prairie, TX 75050
Phone Number (972) 408-1300
Web Address
View Prospectus: Neos Therapeutics
Financial Information
Market Cap $217.4mil
Revenues $0.9 mil (last 12 months)
Net Income $-25.7 mil (last 12 months)
IPO Profile
Symbol NEOS
Exchange NASDAQ
Shares (millions): 4.8
Price range $15.00 - $15.00
Est. $ Volume $72.0 mil
Manager / Joint Managers UBS Investment Bank/ BMO Capital Markets/ RBC Capital Markets
CO-Managers JMP Securities
Expected To Trade: 7/23/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change